drugset

drugset / Trial / NCT00503711

Phase I Chinese PK

NCT00503711 ↗

Phase 1 Completed 36 enrolled Genzyme, a Sanofi Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.

Timeline

Start: 2006-09
Primary completion: 2007-11
Completion: 2007-11

Publications

Background Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vandetanib	Small molecule	100 mg	—
Subject	Vandetanib	Small molecule	300 mg	—

Indications